Nuvation Bio discontinues NUV-1511 drug development program

Nuvation Bio Inc. (NYSE: NUVB) announced November 26 that it will discontinue development of NUV-1511, the first compound in its drug-drug conjugate program. The company cited lack of sufficiently consistent efficacy across patient cohorts as the reason for the decision.

While NUV-1511 was well tolerated and showed promising signals in some patients, the company determined the results were not consistent enough to continue development. The discontinuation affects projected research and development costs of $100-150 million through 2029 that had been budgeted for the compound.

Nuvation Bio stated it will maintain its drug-drug conjugate platform and use information from the NUV-1511 program to evaluate new candidates. Resources previously allocated to NUV-1511 will be transferred to other pipeline molecules and development of next-generation drug-drug conjugate candidates.

The company recently announced the first patient enrollment in part 2 of G203, a global randomized study of safusidenib in high-risk grade 3 or grade 4 IDH1-mutant glioma. Safusidenib is described as a selective, oral mIDH1 inhibitor.

Nuvation Bio will continue investing in the commercial launch of IBTROZI (taletrectinib) and its development program, including enrollment of the TRUST-IV study evaluating the medicine in adjuvant treatment.

You May Also Be Interested In

• Ferguson Enterprises to Join S&P 500; ADI Global Distribution to Join S&P SmallCap 600
• FDA approves Novartis Pluvicto for earlier-stage prostate cancer
• Quince Therapeutics (QNCX) files for 15.47M share offering by selling stockholders